PSYC CEO Ms. Vanessa Luna Resigns Making Way For New Leadership
- Wall Street closes rollercoaster week sharply lower
- Invesco (IVZ) Reportedly in Talks to Merge With State Street's (STT) Asset Management Business, Citi Sees More Cons than Pros
- FDA Votes "No" on Pfizer (PFE) Booster for 16+ Age Group, 2 Yes 16 No
- Jefferies Raises Price Targets on Alphabet (GOOGL) and Facebook (FB) as They Are Still Inexpensive Relative to Growth, Reiterates Snap (SNAP) as a Best Growth Idea
- Tesla (TSLA) Could Deliver 900K EV Units This Year and 1.3M in 2022 - Wedbush
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
SAN DIEGO, July 02, 2020 (GLOBE NEWSWIRE) -- Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) would like to announce to its valued share and stakeholders that Ms. Vanessa Luna has effectively resigned from her role as Chief Executive Officer/ Chairman of the Company which includes the Company’s wholly-owned subsidiary MTrac Tech Corporation (“MTrac”) effective at the end of business on June 30, 2020 and has been succeeded by Global’s former Chief Operating Officer and MTrac’s former VP of Operations, Mr. David A. Flores.
Ms. Luna spearheaded MTrac’s successful launch into the high-risk payment processing market sector which directly contributed to the Company’s first significant revenue earnings in 2019. Additionally, she was instrumental in the Company’s successful completion of its two-year financial audit, making the Company fully audited through 2019, which proved key in creating a level of transparency for shareholders. She has worked in recent months to effectively position PSYC within the emerging medicinal psychedelic industry.
“My time here with Global and MTrac has been a profoundly rewarding and memorable experience for me”, said Ms. Luna. “From the time I joined the Global family in October of 2016, I have dedicated a significant portion of my personal and professional life to the success of this Company and creating something of real value for our share and stakeholders. And despite the multitude of challenges I was faced with throughout that time, I take great pride in what we have been able to accomplish. This decision was not easily made, although I chose this direction following a great deal of personal reflection, in what I believe is a necessary step to poise the Company for future success in the psychedelic space. This arena is uncharted territory for me, and although the business aspect is intriguing, my job is to identify the best path forward. I believe Global will go on to find industry experts, new and exciting management and staff, and will hopefully create a true presence for itself in this space. I find a great deal of peace of mind in knowing that I am leaving the Company in the very capable hands of Mr. Flores who has been alongside me here on this journey since the very beginning of it. Aside from myself, there is truly no one else who has the knowledge and understanding of the corporate and operational structure that makes up Global Trac Solutions today. In speaking with him on multiple occasions, I have become extremely encouraged to more intently understand the passion and energy he has for the medicinal psychedelic reform movement and I am more confident than ever in his capability of helping to successfully lead PSYC into this new and exciting chapter of its history.”
Said new Global Trac Solutions, Inc. CEO, David Flores: “I am both elated and humbled to accept the baton that has been passed over to me from Ms. Luna and accept the distinguished role as CEO and Chairman of Global Trac Solutions. I want to personally thank Ms. Luna for the tremendous sacrifice and hard work she has exhibited over the last few years as CEO of both Global and MTrac. Because of her leadership, the Company today stands in a considerably more adequate, transparent, and effective position than it has perhaps ever before, and I am positively encouraged by the job she has done in recent months with repositioning the Company within an entirely new industry that I believe has a significant amount of growth potential and that I look forward to not only strategically tapping into, but ultimately monetizing for the long-term performance benefit of PSYC. In the coming weeks, it is my intent to share more details as it relates to my vision for continuing and furthering the development of PSYC into a recognized and reputable resource within psychedelics and how I intend to deliver the value that our shareholders truly deserve.”
In closing Ms. Vanessa Luna stated, “To my fellow shareholders, I will be watching alongside you in deep anticipation of the future success of PSYC. It has been my pleasure to serve as your leader these past few years and I hope you will remain faithful and dedicated shareholders in following PSYC’s journey. It has truly been my pleasure, and I extend my sincerest thanks and unwavering gratitude to you all.”
About Global Trac Solutions, Inc. (OTC Pink: PSYC)
Global Trac Solutions is a diversified holding company dedicated to identifying new and emerging industries. By utilizing our years of business development expertise our diverse team of innovators continuously leverages our experience to effectively execute go-to-market strategies in order to position ourselves for rapid growth through the creation of an evolving business foundation to enhance profitability potential.
PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.
We believe in a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future. We truly are the right TRAC to follow.
Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors, including the impact of COVID-10, that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Junshi Biosciences Announces Expansion of Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Post-Exposure Prophylaxis for COVID-19
- Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Whose Tumors
- Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Create E-mail Alert Related CategoriesGlobe Newswire, Press Releases
Related EntitiesEarnings, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!